LAMP1 and classic Hodgkin lymphoma: The addition of rituximab led in samples of EBV- cHL patients to a sixfold increase of the mean frequency of degranulating CD107a+ CD56dim NK cells (Fig. 2a, right part), but only a 2.5-fold increase in EBV+ cHL patients.